OMIX

Retrospective study of new Agents for advanced penile cancer: GSRGT (Global Society of Rare Genitourinary Tumors) paradigm to bring new classes of agents to the clinic to treat an orphan disease

OMIX001508

1Summary
Title Retrospective study of new Agents for advanced penile cancer: GSRGT (Global Society of Rare Genitourinary Tumors) paradigm to bring new classes of agents to the clinic to treat an orphan disease
Description Rare cancers account for 13%-20% of all new cancer diagnoses in the US(1). Penile cancer is one of the rare cancers in developed countries. Approximately 2200 cases are estimated to be diagnosed in the United States in 2021 and nearly 500 deaths. Penile cancer incidence is higher in developing countries and is responsible for as much as 10% of male cancers in developing countries. Risk factors associated with penile cancer include HPV, HIV, phimosis, smoking exposure, and lack of circumcision. Between 30 and 50% of invasive penile carcinomas are human papillomavirus-related (HPV), particularly the high-risk types HPV 16 or 18 with improved outcomes among HPV carriers.This study only collected clinical data of patients with advanced penile cancer who had received immunotherapy in our hospital since 2015 (expected to be no more than 40 patients), including age, smoking history, pathology, CT results, and HPV molecular diagnostic test results, etc. Human samples were not involved.
Organism Homo sapiens
Data Type Clinical Research data
Data Accessibility Controlled-access
BioProject PRJCA011022
Release Date 2022-08-06
Submitter hui han (hanhui@sysucc.org.cn)
Organization Sun Yat-sen University Cancer Center
Submission Date 2022-08-05
2Files & Download

HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).

File ID File Title Number/Samples File Type File Size File Suffix Download Times Download
OMIX001508-01 Retrospective study of new Agents for advanced penile cancer: GSRGT (Global Society of Rare Genitourinary Tumors) paradigm to bring new classes of agents to the clinic to treat an orphan disease 40 Clinical Research data 770.1 KB xlsx 0 Controlled

Request for this Data View All Released Data of OMIX